EU Medicines Regulation Achievements: EMA’s 2025 Highlights and Future Directions

The European Medicines Agency (EMA) Management Board highlights at its March 2026 meeting a robust year, with the adoption of the 2025 annual report detailing 104 positive recommendations for new human medicines—including 38 with new active substances—and 30 for veterinary medicines, the highest in two years. Key steps emphasized optimizing assessments, enhancing access, implementing the Health Technology Assessment (HTA) Regulation, mitigating shortages, and bolstering the EU medicines regulatory network’s resilience. These accomplishments position EMA as a pivotal force in ensuring timely and reliable medicines availability across the European Union.

Regulatory Optimization Surge

The Board’s focus on regulatory evolution points to impactful strides in preparing for the new EU pharmaceutical legislation, where governance structures are now largely established, including nominated leads for workstreams and confirmed sponsors from EMA, the European Commission, and national authorities. The 2025 report highlights EMA’s delivery of high-volume recommendations amid efforts to streamline processes, such as coordinating HTA Regulation implementation to harmonize health technology assessments for more efficient market access. This groundwork ensures that, post-formal adoption by the Council and Parliament, delegated acts and EMA guidance will facilitate compliance, directly addressing trends in faster medicines evaluation and reduced duplication in HTA activities—core to broader EU Medicines Regulation Achievements.

ePI Roadmap Endorsed

Building on legislative readiness, the Board’s endorsement of the electronic product information (ePI) draft roadmap marks a transformative step toward mandatory ePI for newly authorized medicines under the forthcoming legislation, aiming to deliver timely, accurate, and accessible data to patients and healthcare professionals. The 2024-2025 stakeholder engagement report further amplifies this by detailing contributions from patient groups, healthcare professionals, academia, and industry to core EMA functions like medicines evaluation and safety monitoring, as well as strategic initiatives such as the European Medicines Agencies Network Strategy to 2028, artificial intelligence ethics, and patient experience data reflection papers.

Lowering Barriers to Innovative Therapies

These developments may potentially lower barriers to innovative therapies and informing accelerated reimbursement decisions. For instance, the high volume of new active substance recommendations and ePI mandate could enhance evidence collection for HEOR studies, enabling more precise cost-effectiveness analyses amid rising costs.